Contact Us
Drug Search Results
More Filters [+]

CGT-6321

Alternative Names: CGT-6321, CGT6321, CGT 6321
Latest Update: None
Latest Update Note: None

Product Description

CGT-6321 tablet is a FGFR/VEGFR double antibody, which can relieve immunosuppression, anti-angiogenesis, and then inhibit tumor growth. (Sourced from: https://min.news/en/health/422c40140d96004bf6e81df2be852101.html_

Mechanisms of Action: VEGFR Inhibitor,FGFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Shengshi Taike Biomedical Technology (Suzhou) Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CGT-6321

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CTR20220319

P1

Not yet recruiting

Oncology Solid Tumor Unspecified

None

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions